198 related articles for article (PubMed ID: 30909072)
1. Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort.
Tétu P; Allayous C; Oriano B; Dalle S; Mortier L; Leccia MT; Guillot B; Dalac S; Dutriaux C; Lacour JP; Saiag P; Brunet-Possenti F; De Quatrebarbes J; Stoebner PE; Legoupil D; Beylot-Barry M; Lesimple T; Aubin F; Dreno B; Mohamed S; Ballon A; Porcher R; Lebbe C
Eur J Cancer; 2019 May; 112():38-46. PubMed ID: 30909072
[TBL] [Abstract][Full Text] [Related]
2. Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy : Melanoma brain metastases prognostic score.
Schaule J; Kroeze SGC; Blanck O; Stera S; Kahl KH; Roeder F; Combs SE; Kaul D; Claes A; Schymalla MM; Adebahr S; Eckert F; Lohaus F; Abbasi-Senger N; Henke G; Szuecs M; Geier M; Sundahl N; Buergy D; Dummer R; Guckenberger M
Radiat Oncol; 2020 Jun; 15(1):135. PubMed ID: 32487100
[TBL] [Abstract][Full Text] [Related]
3. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.
Rauschenberg R; Bruns J; Brütting J; Daubner D; Lohaus F; Zimmer L; Forschner A; Zips D; Hassel JC; Berking C; Kaehler KC; Utikal J; Gutzmer R; Terheyden P; Meiss F; Rafei-Shamsabadi D; Kiecker F; Debus D; Dabrowski E; Arnold A; Garzarolli M; Kuske M; Beissert S; Löck S; Linn J; Troost EGC; Meier F
Eur J Cancer; 2019 Mar; 110():11-20. PubMed ID: 30739835
[TBL] [Abstract][Full Text] [Related]
4. Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.
Sloot S; Chen YA; Zhao X; Weber JL; Benedict JJ; Mulé JJ; Smalley KS; Weber JS; Zager JS; Forsyth PA; Sondak VK; Gibney GT
Cancer; 2018 Jan; 124(2):297-305. PubMed ID: 29023643
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.
Gabani P; Fischer-Valuck BW; Johanns TM; Hernandez-Aya LF; Keller JW; Rich KM; Kim AH; Dunn GP; Robinson CG; Chicoine MR; Huang J; Abraham CD
Radiother Oncol; 2018 Aug; 128(2):266-273. PubMed ID: 29960685
[TBL] [Abstract][Full Text] [Related]
6. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG.
Franklin C; Mohr P; Bluhm L; Grimmelmann I; Gutzmer R; Meier F; Garzarolli M; Weichenthal M; Pfoehler C; Herbst R; Terheyden P; Utikal J; Ulrich J; Debus D; Haferkamp S; Kaatz M; Forschner A; Leiter U; Nashan D; Kreuter A; Sachse M; Welzel J; Heinzerling L; Meiss F; Weishaupt C; Gambichler T; Weyandt G; Dippel E; Schatton K; Celik E; Trommer M; Helfrich I; Roesch A; Zimmer L; Livingstone E; Schadendorf D; Horn S; Ugurel S
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688555
[TBL] [Abstract][Full Text] [Related]
7. Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-A retrospective cohort study.
Gatterbauer B; Hirschmann D; Eberherr N; Untersteiner H; Cho A; Shaltout A; Göbl P; Fitschek F; Dorfer C; Wolfsberger S; Kasprian G; Höller C; Frischer JM
Cancer Med; 2020 Jun; 9(11):4026-4036. PubMed ID: 32249551
[TBL] [Abstract][Full Text] [Related]
8. Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
Bander ED; Yuan M; Carnevale JA; Reiner AS; Panageas KS; Postow MA; Tabar V; Moss NS
Cancer; 2021 Jun; 127(12):2062-2073. PubMed ID: 33651913
[TBL] [Abstract][Full Text] [Related]
9. Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort.
Iorgulescu JB; Harary M; Zogg CK; Ligon KL; Reardon DA; Hodi FS; Aizer AA; Smith TR
Cancer Immunol Res; 2018 Sep; 6(9):1039-1045. PubMed ID: 30002157
[TBL] [Abstract][Full Text] [Related]
10. The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis.
Rulli E; Legramandi L; Salvati L; Mandala M
Cancer; 2019 Nov; 125(21):3776-3789. PubMed ID: 31287564
[TBL] [Abstract][Full Text] [Related]
11. Melanoma brain metastases - Interdisciplinary management recommendations 2020.
Gutzmer R; Vordermark D; Hassel JC; Krex D; Wendl C; Schadendorf D; Sickmann T; Rieken S; Pukrop T; Höller C; Eigentler TK; Meier F
Cancer Treat Rev; 2020 Sep; 89():102083. PubMed ID: 32736188
[TBL] [Abstract][Full Text] [Related]
12. Validation of the Chowdhury overall survival score in patients with melanoma brain metastasis treated with Gamma Knife Radiosurgery.
Rodenburg RJ; Hanssens PE; Ho VKY; Beerepoot LV
J Neurooncol; 2018 Jun; 138(2):391-399. PubMed ID: 29470692
[TBL] [Abstract][Full Text] [Related]
13. Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade.
Milsch L; Gesierich A; Kreft S; Livingstone E; Zimmer L; Goebeler M; Schadendorf D; Schilling B
Eur J Cancer; 2018 Aug; 99():58-65. PubMed ID: 29906735
[TBL] [Abstract][Full Text] [Related]
14. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.
Schvartsman G; Ma J; Bassett RL; Haydu LE; Amaria RN; Hwu P; Wong MK; Hwu WJ; Diab A; Patel SP; Davies MA; Hamerschlak N; Tawbi HA; Glitza Oliva IC
Cancer; 2019 Dec; 125(23):4193-4202. PubMed ID: 31398264
[TBL] [Abstract][Full Text] [Related]
15. First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma.
Wang X; Haaland B; Hu-Lieskovan S; Colman H; Holmen SL
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1419. PubMed ID: 34137219
[TBL] [Abstract][Full Text] [Related]
16. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies.
Choong ES; Lo S; Drummond M; Fogarty GB; Menzies AM; Guminski A; Shivalingam B; Clarke K; Long GV; Hong AM
Eur J Cancer; 2017 Apr; 75():169-178. PubMed ID: 28236768
[TBL] [Abstract][Full Text] [Related]
17. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
[TBL] [Abstract][Full Text] [Related]
18. The changing paradigm of management in melanoma brain metastases.
Ladwa R; Atkinson V
Asia Pac J Clin Oncol; 2018 Dec; 14(6):453-458. PubMed ID: 29932306
[TBL] [Abstract][Full Text] [Related]
19. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
[TBL] [Abstract][Full Text] [Related]
20. The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy.
Kaidar-Person O; Zagar TM; Deal A; Moschos SJ; Ewend MG; Sasaki-Adams D; Lee CB; Collichio FA; Fried D; Marks LB; Chera BS
Anticancer Drugs; 2017 Jul; 28(6):669-675. PubMed ID: 28368903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
